| Literature DB >> 33838655 |
Chenting Hou1, Hui Li2,3, Jiangfeng Li1, Jinjian Li1, Hui Peng1, Qing Wang4.
Abstract
BACKGROUND: To compare the postoperative safety, efficacy, predictability, visual quality and biomechanics after implantation of Artisan vs. Artiflex phakic intraocular lenses (PIOLs).Entities:
Keywords: Artiflex PIOL; Artisan PIOL; Meta-analysis; Myopia
Year: 2021 PMID: 33838655 PMCID: PMC8035774 DOI: 10.1186/s12886-021-01930-6
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
Fig. 1Flowchart for the studies analysis
Basic characteristics of included trials
| Country | type | Age | Sex(F/M) | |||
|---|---|---|---|---|---|---|
| Artisan | Artiflex | Artisan | Artiflex | |||
| Hedayatfar et.al(2017) [ | Iran | Prospective | 25.5 ± 6.0 | 27.8 ± 4.8 | 1.29 | 2.28 |
| Parsipour et.al(2016) [ | Iran | Prospective | NR | NR | NR | NR |
| Aerts et.al(2015) [ | Netherland | Retrospective | 51.2 ± 10.1 | 45.5 ± 11.3 | 238/133 | 171/86 |
| Karimian et.al(2014) [ | Iran | Historical cohort | 27 ± 3 | 30 ± 5 | NR | NR |
| Alio et.al(2013) [ | Spain | Retrospective | 32 ± 11.46 | 36.81 ± 8.28 | NR | NR |
| Shin et.al.(2013) [ | Korea | Retrospective | 31.75 ± 8.30 | 31.47 ± 6.39 | 32/8 | 27/9 |
| Torri et.al (2013) [ | Japan | Retrospective | 39.2 ± 8.1 | 37.6 ± 7.2 | NR | NR |
| Peris-Martinez et.al(2009) [ | Spain | Retrospective | 30 ± 5 | 33 ± 6 | NR | NR |
| Kohnen et.al(2008) [ | USA | Retrospective | 32 ± 10 | 34 ± 10 | 7/2 | 7/1 |
| Tahzib et.al(2008) [ | USA | Retrospective | 40.0 ± 12.0 | 41.0 ± 7.8 | 8/19 | 13/9 |
| Coullet et.al (2006) [ | France | Double-blind | 37.8 ± 9 | 37.8 ± 9 | NR | NR |
Basic characteristics of included trials
| Eyes | Follow-up | pre SE | ||||
|---|---|---|---|---|---|---|
| Artisan | Artiflex | Artisan | Artiflex | Artisan | Artiflex | |
| Hedayatfar et.al(2017) [ | 16 | 56 | 1w,1 m,3 m,6 m,12 m | −16.64 ± 6.83 | −10.33 ± 3.15 | |
| Parsipour et.al(2016) [ | 24 | 33 | 12 m | −10.39 ± 8.43 | − 10.39 ± 2.29 | |
| Aerts et.al(2015) [ | 371 | 257 | 17 ± 7.2(6 m, 1y, 2y) | −12.7 ± 5.0 | −9.29 ± 2.8 | |
| Karimian et.al(2014) [ | 40 | 36 | 30 ± 11 m | −11.6 ± 3.7 | −9.59 ± 1.97 | |
| Alio et.al(2013) [ | 16 | 15 | NR | −13.38 ± 4.33 | −11.32 ± 3.10 | |
| Shin et.al.(2013) [ | 40 | 36 | 3 m | −9.88 ± 2.19 | −7.67 ± 1.92 | |
| Torri et.al (2013) [ | 23 | 30 | 6 m | −11.84 ± 4.9 | − 9.78 ± 3.2 | |
| Peris-Martinez et.al(2009) [ | 12 | 18 | 12 m | −9.2 ± 2.6 | − 9.6 ± 2.6 | |
| Kohnen et.al(2008) [ | 15 | 15 | 6, 12 m | −10.23 ± 1.92 | −8.78 ± 1.56 | |
| Tahzib et.al(2008) [ | 22 | 27 | 1w, 1 m, 3 m, 12 m | −9.9 ± 2.74 | −9.95 ± 1.43 | |
| Coullet et.al (2006) [ | 31 | 31 | 12 m | −10.3 ± 3.2 | −9.5 ± 2.2 | |
Footnotes: F/M means female/male, Pre SE means spherical equivalent before surgery, NR not reported in this study
Quality assessment of included studies
| Included in research | Random Allocation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personal (implemention bias) | Blinding of outcome assessment (measurement bias) | Selective reporting (reporting bias) | Incomplete outcome data (follow-up bias) | Other bias | Quality level |
|---|---|---|---|---|---|---|---|---|
| Hedayatfar et.al | H | U | U | U | L | L | L | B |
| Parsipour et.al | H | U | U | U | L | L | L | B |
| Aerts et.al | H | U | U | U | L | H | L | B |
| Karimian et.al | H | U | U | U | L | L | L | B |
| Alio et.al | H | U | U | U | L | L | L | B |
| Shin et.al. | H | U | U | U | L | L | L | B |
| Torri et.al | H | U | U | U | L | L | L | B |
| Peris-Martinez et.al | H | U | U | U | L | L | L | B |
| Kohnen et.al | H | U | U | U | L | L | L | B |
| Tahzib et.al | H | U | U | U | L | L | L | B |
| Collet et.al | H | L | L | L | L | L | L | A |
H high risk of bias, U unclear, L low risk of bias
Fig. 2a shows forest plot of safety index; b shows forest plot of efficacy index
WMD of SE and Odds Ratio of proportion of eyes with SE within ±1.0 D 1 year after operation
| Study (publication year) | Follow-up | SE value | SE within ±1D | ||
|---|---|---|---|---|---|
| WMD [95% CI] | %Weight | OR[95% CI] | %Weight | ||
| Parsipour et.al(2016) [ | 1y | −0.39[− 0.974,0.194] | 8.48 | 0.378 [0.122,1.172] | 38.33 |
| Karimian et.al(2014) [ | 30 ± 11 | −0.38[− 0.587,-0.173] | 27.78 | 0.136 [0.036,0.521] | 27.27 |
| Tahzib et.al(2008) [ | 1y | 0.02[−0.221,0.261] | 24.88 | / | / |
| Kohnen et.al(2008) [ | 1y | −0.16[− 0.479,0.159] | 19.16 | / | / |
| Coullet et.al(2006) [ | 1y | −0.43[− 0.741,-0.119] | 19.70 | 0.266 [0.081,0.879] | 34.39 |
| Combined effect size | Pooled WMD[95% CI]: −0.249[− 0.44,-0.058], Test of WMD = 0: z = 2.56, p = 0.01* | Pooled OR[95% CI] 0.254 [0.126,0.511], Test of OR = 1: z = 3.84, | |||
| Heterogeneity | chi2 = 8.15(d.f. = 4), I2 = 50.9%, | Chi2 = 1.32(d.f. = 2), | |||
SE spherical equivalent
Fig. 3Forest plot of the intraocular high-order aberrations. a shows forest plots of vertical trefoil, vertical coma, horizontal coma, horizontal trefoil; b shows forest plot of spherical aberration; c shows forest plot of total high-order aberration
Sensitivity analysis outcomes of postoperative BCVA and SA
| Combined effect size | Heterogeneity | ||
|---|---|---|---|
| BCVA | Exclude Shin et.al | WMD [95%CI] 0.097 (0.044,0.15), p < 0.01 | I2 = 72.4%, |
| Exclude Tahzib et.al | WMD [95%CI]0.063 (−0.017,0.143), | I2 = 91.8%, P < 0.01 | |
| SA | Before excluding | WMD[95%CI]: 0.104[−0.327,0.535], | Chi2 = 63.24(d.f. = 3) p = 0.0, I2 = 95.3% |
| Exclude Karimian et.al | WMD[95%CI]: 0.232[−0.202,0.666], | Chi2 = 24.79(d.f. = 2) p = 0.0, I2 = 91.9% | |
| Exclude Tahzib et.al | WMD[95%CI]:-0.076[−0.321,0.169], | Chi2 = 8.18(d.f. = 2) | |
| Exclude Torri et.al | WMD[95%CI]:0.074[−0.467, 0.616], | Chi2 = 62.68(d.f. = 2) p = 0.0, I2 = 96.8% | |
| Exclude Alio et.al | WMD[95%CI]:0.169[−0.406, 0.744], | Chi2 = 59.79(d.f. = 2) p = 0.0, I2 = 96.7% |
BCVA best corrected visual acuity, SA spherical aberration
Fig. 4Forest plots of the subgroup analysis for spherical aberration (SA). a shows subgroup plot divided by age; b shows subgroup plot divided by aberrometer type
Fig. 5Forest plots of subgroup analysis for total high-order aberration (THOA). a shows subgroup plot divided by age; b shows subgroup plot divided by trial type